 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...174175176177178179180181182183184...235236» |
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 12, 2019
P2, N=120, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2018 --> Nov 2019
- | Trial completion date, Trial primary completion date, Metastases: PaFLO: FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (clinicaltrials.gov) - Feb 12, 2019
P2, N=75, Completed, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Dec 2018 --> Nov 2019 Trial completion date: May 2015 --> Dec 2017 | Trial primary completion date: May 2014 --> Dec 2017
- | EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 12, 2019
P1/2, N=2, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: May 2015 --> Dec 2017 | Trial primary completion date: May 2014 --> Dec 2017 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- | Enrollment open: Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX (clinicaltrials.gov) - Feb 12, 2019
P=N/A, N=60, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Not yet recruiting --> Recruiting
- | New trial, BRCA Biomarker, Metastases: BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer (clinicaltrials.gov) - Feb 11, 2019
P=N/A, N=30, Recruiting, Sponsor: Chung-Ang University
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial: NET-02: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (clinicaltrials.gov) - Feb 11, 2019
P2, N=102, Recruiting, Sponsor: Dr Mair
- | Kinaction (masitinib) / AB Science
Enrollment change, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 11, 2019
P3, N=123, Terminated, Sponsor: AB Science
Not yet recruiting --> Recruiting N=186 --> 123
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Feb 11, 2019
P1, N=28, Active, not recruiting, Sponsor: AstraZeneca
N=186 --> 123 Recruiting --> Active, not recruiting | N=42 --> 28 | Trial completion date: Jun 2019 --> Mar 2020 | Trial primary completion date: Jun 2019 --> Mar 2020
- || veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy, Metastases: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 8, 2019
P1/2, N=64, Active, not recruiting, Sponsor: Georgetown University
Recruiting --> Active, not recruiting | N=42 --> 28 | Trial completion date: Jun 2019 --> Mar 2020 | Trial primary completion date: Jun 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- || Vectibix (panitumumab) / Amgen
Enrollment closed: OPALO: FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (clinicaltrials.gov) - Feb 8, 2019
P2, N=80, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial initiation date, Metastases: A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer (clinicaltrials.gov) - Feb 8, 2019
P2, N=120, Not yet recruiting, Sponsor: Yonsei University
Recruiting --> Active, not recruiting Trial completion date: Aug 2022 --> Jun 2022 | Initiation date: Sep 2018 --> Mar 2019
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment closed, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Feb 7, 2019
P1b, N=205, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Aug 2022 --> Jun 2022 | Initiation date: Sep 2018 --> Mar 2019 Recruiting --> Active, not recruiting
- | Trial completion: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Feb 6, 2019
P2, N=48, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| AryoTrust (trastuzumab biosimilar) / Inno Bio, AryoGen Pharmed, Stivant (bevacizumab biosimilar) / AryoGen Pharmed
Trial completion, Trial primary completion date, Head-to-Head: Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 6, 2019
P3, N=126, Completed, Sponsor: AryoGen Pharmed Co.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Jul 2018
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date, Surgery: acns0333: Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov) - Feb 5, 2019
P3, N=70, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Jul 2018 Trial primary completion date: Apr 2015 --> Sep 2016
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Feb 5, 2019
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2015 --> Sep 2016 Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020
- | Trial withdrawal: Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma (clinicaltrials.gov) - Feb 5, 2019
P2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020 Terminated --> Withdrawn
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Feb 4, 2019
P1, N=66, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Terminated --> Withdrawn Trial completion date: Feb 2019 --> Dec 2019
- | Avastin (bevacizumab) / Roche
New P3 trial, HEOR, Metastases: COLAGE: QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (clinicaltrials.gov) - Feb 4, 2019
P3, N=188, Not yet recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- | Stivarga (regorafenib) / Bayer
New P1/2 trial, Combination therapy, Metastases: FOLFIRINOX-R: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (clinicaltrials.gov) - Feb 4, 2019
P1/2, N=87, Not yet recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
Clinical, Journal: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. (Pubmed Central) - Feb 1, 2019
Sequential therapy with nab-P + Gem followed by nal-IRI + 5-FU/LV demonstrates encouraging median OS. These findings provide guidance for patients most likely to benefit from nal-IRI + 5-FU/LV.
- | Trial completion date: Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer (clinicaltrials.gov) - Feb 1, 2019
P2, N=67, Active, not recruiting, Sponsor: Washington University School of Medicine
These findings provide guidance for patients most likely to benefit from nal-IRI + 5-FU/LV. Trial completion date: Jul 2021 --> Dec 2019
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 1, 2019
P3, N=172, Recruiting, Sponsor: Stanford University
Trial completion date: Jul 2021 --> Dec 2019 Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2018 --> Sep 2020
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, BRCA Biomarker, PARP Biomarker, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Feb 1, 2019
P2, N=110, Recruiting, Sponsor: Academic and Community Cancer Research United
Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2018 --> Sep 2020 Not yet recruiting --> Recruiting
- | New P2 trial, Metastases: Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov) - Jan 31, 2019
P2, N=27, Recruiting, Sponsor: Instituto do Cancer do Estado de S
- | New P2 trial: PIOPPO: Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma (clinicaltrials.gov) - Jan 29, 2019
P2, N=30, Recruiting, Sponsor: CNAO National Center of Oncological Hadrontherapy
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Metastases: Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients (clinicaltrials.gov) - Jan 29, 2019
P4, N=1500, Active, not recruiting, Sponsor: Asan Medical Center
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Dec 2019
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Surgery, Metastases: ADORE: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer (clinicaltrials.gov) - Jan 29, 2019
P2, N=320, Active, not recruiting, Sponsor: Asan Medical Center
Trial completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Dec 2020
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Metastases: Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 29, 2019
P2, N=180, Completed, Sponsor: Yonsei University
Trial completion date: Dec 2018 --> Dec 2020 Active, not recruiting --> Completed
- ||||| Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
Enrollment closed, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 28, 2019
P3, N=645, Active, not recruiting, Sponsor: Array BioPharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Kinaction (masitinib) / AB Science
Trial primary completion date, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 28, 2019
P2/3, N=219, Active, not recruiting, Sponsor: AB Science
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2018 --> Dec 2020
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial completion date, Metastases: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. (clinicaltrials.gov) - Jan 25, 2019
P2, N=21, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial primary completion date: Dec 2018 --> Dec 2020 Recruiting --> Completed | N=127 --> 21 | Trial completion date: Nov 2019 --> Apr 2017
- || Ninlaro (ixazomib) / Takeda
New P1/2 trial, Combination therapy: T2017-002: PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov) - Jan 24, 2019
P1/2, N=31, Recruiting, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
- | AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date, Combination therapy, Metastases: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) (clinicaltrials.gov) - Jan 23, 2019
P2, N=80, Recruiting, Sponsor: Shenzhen People's Hospital
Recruiting --> Completed | N=127 --> 21 | Trial completion date: Nov 2019 --> Apr 2017 Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> May 2018
- | New P2 trial, Metastases: Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC (clinicaltrials.gov) - Jan 23, 2019
P2, N=70, Recruiting, Sponsor: Sun Yat-sen University
- | New P2 trial, Metastases: HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC (clinicaltrials.gov) - Jan 23, 2019
P2, N=100, Recruiting, Sponsor: Sun Yat-sen University
- | Enrollment closed, Enrollment change: Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 22, 2019
P2, N=9, Active, not recruiting, Sponsor: Yale University
Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> May 2018 Recruiting --> Active, not recruiting | N=28 --> 9
- | Enrollment open: INTENSE: Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov) - Jan 22, 2019
P2, N=60, Recruiting, Sponsor: Lund University Hospital
Recruiting --> Active, not recruiting | N=28 --> 9 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) (clinicaltrials.gov) - Jan 19, 2019
P2, N=30, Recruiting, Sponsor: Shanghai Changzheng Hospital
- | Avastin (bevacizumab) / Roche
Biomarker, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jan 18, 2019
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2018 --> Jul 2019
- | Enrollment open: PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 17, 2019
P2, N=216, Recruiting, Sponsor: Mian XI
Trial primary completion date: Dec 2018 --> Jul 2019 Not yet recruiting --> Recruiting
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer (clinicaltrials.gov) - Jan 16, 2019
P2, N=30, Active, not recruiting, Sponsor: Bruckner Oncology
Not yet recruiting --> Recruiting Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: Aug 2018 --> Feb 2019
- |||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Metastases: AtezoTRIBE: FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jan 16, 2019
P2, N=201, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: Aug 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- |||| Tedopi (OSE 2101) / OSE Immunotherapeutics
New P2 trial, Combination therapy, Metastases: TEDOPAM: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jan 16, 2019
P2, N=156, Not yet recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- | oxaliplatin / Generic mfg.
Trial completion date, Trial primary completion date: Lidocaine for Oxaliplatin-induced Neuropathy (clinicaltrials.gov) - Jan 15, 2019
P1/2, N=38, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
- | Erbitux (cetuximab) / Eli Lilly
Biomarker, Trial completion date, Trial primary completion date, Metastases: Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 14, 2019
P2, N=30, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Aug 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | New P3 trial: NRG-GI006: Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (clinicaltrials.gov) - Jan 14, 2019
P3, N=300, Not yet recruiting, Sponsor: NRG Oncology
- | New P3 trial, MSi-H Biomarker, PD(L)-1 Biomarker: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Jan 13, 2019
P3, N=400, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | gemcitabine / Generic mfg.
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. (Pubmed Central) - Jan 12, 2019
P3
Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
- | NN1213 / Novo Nordisk
Trial termination: The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial (clinicaltrials.gov) - Jan 11, 2019
P2/3, N=79, Terminated, Sponsor: Sun Yat-sen University
(Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .). Completed --> Terminated; protocol violation